LifeMD Inc expected to post a loss of 5 cents a share - Earnings Preview

LifeMD

07/03/2025 20:27

LifeMD Inc LFMD.OQ LFMD.O is expected to show a rise in quarterly revenue when it reports  results on March 10 for the period ending December 31 2024

The New York City-based  company is expected to report a 27.9% increase in revenue to $57.385 million from $44.86 million a year ago, according to the mean estimate from 9 analysts, based on LSEG data.The company's guidance on November 7 2024, for the period ended December 31, was for revenue between $57.00 million and $58.00 million.

​LSEG's mean analyst estimate for LifeMD Inc is for a loss of 5 cents per share.

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 8 "strong buy" or "buy," 1 "hold" and no "sell" or "strong sell."

The mean earnings estimate of analysts was unchanged in the last three months. ​

Wall Street's median 12-month price target for LifeMD Inc is $12.00​, above​ its last closing price of $4.83. ​​​

The company's guidance on November 7 2024 for the period ended December 31 was for Earnings before Interest, Taxes, Depreciation and Amortization of between USD57 million and USD7 million.

Previous quarterly performance (using preferred earnings measure in US dollars). ​

QUARTER ENDING
STARMINESMARTESTIMATE®
LSEG IBES ESTIMATE
ACTUAL
BEAT, MET, MISSED
SURPRISE %
Sep. 30 2024
-0.12
-0.12
-0.14
Missed
-18
Jun. 30 2024
-0.14
-0.12
-0.19
Missed
-52
Mar. 31 2024
-0.16
-0.15
-0.19
Missed
-23.4​
Dec. 31 2023
-0.12
-0.14
-0.12
Beat
14.3
​​Sep. 30 2023
-0.15
-0.15
-0.20
Missed
-29
Jun. 30 2023
-0.10
-0.10
-0.23
Missed
-122.6​
Mar. 31 2023
-0.16
-0.16
-0.15
Beat
6.3
Dec. 31 2022
-0.18
-0.18
-0.40
Missed
-122.2

This summary was machine generated March 7 at 20:27 GMT.  All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)